Successful treatment with antivirals reduces the incidence of some extrahepatic manifestations of HCV. Thus, the advent of well-tolerated and highly potent antiviral regimens might enable extension of the indication for therapy to patients at risk of developing serious extrahepatic disorders, irrespective of the severity of the underlying liver disease.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
HCV co-infection is related to acute ischemic severity and outcome
The Egyptian Journal of Internal Medicine Open Access 15 January 2022
-
HCV monoinfection and HIV/HCV coinfection enhance T-cell immune senescence in injecting drug users early during infection
Immunity & Ageing Open Access 31 March 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Thomas, D. L. Global control of hepatitis C: where challenge meets opportunity. Nat. Med. 19, 850–858 (2013).
Jacobson, I. M., Cacoub, P., Dal Maso, L., Harrison, S. A. & Younossi, Z. M. Manifestations of chronic hepatitis C virus infection beyond the liver. Clin. Gastroenterol. Hepatol. 8, 1017–1029 (2010).
Fletcher, N. F. et al. Hepatitis C virus infects the endothelial cells of the blood–brain barrier. Gastroenterology 142, 634–643 (2012).
Vanni, E. et al. Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology 50, 697–706 (2009).
van der Meer, A. J. et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308, 2584–2593 (2012).
Younossi, Z. M., Stepanova, M., Nader, F., Younossi, Z. & Elsheikh, E. Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment. Pharmacol. Ther. 37, 647–652 (2013).
Kakinami, L. et al. Risk of cardiovascular disease in HIV, hepatitis C, or HIV/hepatitis C patients compared to the general population. Int. J. Clin. Pract. 67, 6–13 (2013).
Hsu, C. S. et al. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan. Aliment. Pharmacol. Ther. 38, 415–423 (2013).
Hsu, Y. C. et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology http://dx.doi.org/10.1002/hep.26892.
Arase, Y. et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 49, 739–744 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
F. Negro is a consultant for Roche and MSD; advises Boehringer Ingelheim, Gilead, Janssen, MSD, Novartis and Roche, and has received unrestricted research grants from Gilead, Novartis and Roche.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Negro, F. HCV causes systemic disorders that can be cured. Nat Rev Gastroenterol Hepatol 11, 77–78 (2014). https://doi.org/10.1038/nrgastro.2013.222
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2013.222
This article is cited by
-
HCV co-infection is related to acute ischemic severity and outcome
The Egyptian Journal of Internal Medicine (2022)
-
HCV monoinfection and HIV/HCV coinfection enhance T-cell immune senescence in injecting drug users early during infection
Immunity & Ageing (2016)
-
Elevated hepatic lipid and interferon stimulated gene expression in HCV GT3 patients relative to non-alcoholic steatohepatitis
Hepatology International (2016)
